The advent of biologic agents that specifically inhibit IL-1 has dramatically improved clinical outcomes for many children with sJIA and confirmed the pathogenic role of this cytokine in disease processes. This evidence concerns the gene IL1B and systemic-onset juvenile idiopathic arthritis.